Determine 10-Q 14 Feb 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Dec. 31, 2013	Feb. 03, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'SELECTICA INC	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--03-31	'
Entity Common Stock, Shares Outstanding	'	4,773,722
Amendment Flag	'false	'
Entity Central Index Key	'0001090908	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Dec. 31, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$9,721	$12,098
Accounts receivable, net of allowance for doubtful accounts of $144 and $111 as of December 31, 2013 and March 31, 2013, respectively	4,040	3,455
Prepaid expenses and other current assets	538	853
Total current assets	14,299	16,406
Property and equipment, net	317	407
Capitalized software	661	'
Other assets	40	39
Total assets	15,317	16,852
Current liabilities	'	'
Credit facility	6,234	6,000
Accounts payable	1,002	1,010
Accrued payroll and related liabilities	413	982
Accrued restructuring costs	49	232
Other accrued liabilities	291	163
Deferred revenue	5,275	6,153
Total current liabilities	13,264	14,540
Long-term deferred revenue	816	1,772
Other long-term liabilities	'	20
Total liabilities	14,080	16,332
Commitments and contingencies (See Note 9)	'	'
Common stock, $0.0001 par value: Authorized 15,000 shares at December 31, 2013 and March 31, 2013; Issued 3,960 and 2,983 at December 31, 2013 and March 31, 2013, respectively; Outstanding 3,864 and 2,887 at December 31, 2013 and March 31, 2013, respectively	4	4
Additional paid-in capital	273,067	267,339
Treasury stock at cost - 96 shares at December 31, 2013 and March 31, 2013	-472	-472
Accumulated deficit	-271,362	-266,351
Total stockholders' equity	1,237	520
Total liabilities and stockholders' equity	$15,317	$16,852

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Dec. 31, 2013	Mar. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
Accounts receivable, allowance for doubtful accounts (in Dollars)	$144	$111
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, authorized	15,000	15,000
Common stock, issued	3,960	2,983
Common stock, outstanding	3,864	2,887
Treasury stock shares	96	96

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Operating expenses:	'	'	'	'
Research and development	$586	$950	$2,139	$2,742
Sales and marketing	2,051	1,642	6,254	4,887
General and administrative	1,349	985	3,636	2,554
Restructuring costs	'	'	227	'
Fees related to comprehensive settlement agreement	'	'	'	500
Total operating expenses	3,986	3,577	12,256	10,683
Loss from operations	-2,169	-1,055	-5,997	-2,642
Decrease in fair value of warrant liability	'	'	982	'
Interest and other income (expense), net	45	-3	4	-14
Net loss	-2,124	-1,058	-5,011	-2,656
Series C redeemable preferred stock accretion	'	'	1,621	'
Net loss applicable to common stockholders	-2,124	-1,058	-6,632	-2,656
Basic and diluted net loss per common share applicable to common stockholders (in Dollars per share)	($0.55)	($0.37)	($1.88)	($0.94)
Weighted average shares outstanding for basic and diluted net loss per share applicable to common shareholder (in Shares)	3,877	2,830	3,522	2,818
Recurring [Member]	'	'	'	'
Revenues:	'	'	'	'
Total revenues	3,091	3,054	9,277	8,650
Cost of revenues:	'	'	'	'
Total cost of revenues	634	489	2,000	1,227
Gross profit:	'	'	'	'
Total gross profit	2,457	2,565	7,277	7,423
Non-Recurring [Member]	'	'	'	'
Revenues:	'	'	'	'
Total revenues	857	1,442	2,971	4,677
Cost of revenues:	'	'	'	'
Total cost of revenues	1,497	1,485	3,989	4,059
Gross profit:	'	'	'	'
Total gross profit	-640	-43	-1,018	618
Recurring And Non Recurring [Member]	'	'	'	'
Revenues:	'	'	'	'
Total revenues	3,948	4,496	12,248	13,327
Cost of revenues:	'	'	'	'
Total cost of revenues	2,131	1,974	5,989	5,286
Gross profit:	'	'	'	'
Total gross profit	$1,817	$2,522	$6,259	$8,041

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Operating activities	'	'
Net loss	($5,011)	($2,656)
Depreciation	146	156
Loss on disposition of property and equipment	23	'
Stock-based compensation expense	902	699
Decrease in warrant liability	-982	'
Changes in assets and liabilities:	'	'
Accounts receivable (net)	-585	-2,145
Prepaid expenses and other current assets	314	-91
Other assets	-1	'
Accounts payable	-10	356
Restructuring liability	-183	'
Accrued payroll and related liabilities	-569	-951
Other accrued liabilities and long term liabilities	108	-12
Deferred revenue	-1,835	-1,216
Net cash used in operating activities	-7,683	-5,860
Investing activities	'	'
Purchase of property and equipment	-79	-193
Capitalized software	-661	'
Proceeds from maturities of short-term investments	'	199
Net cash (used in) provided by investing activities	-740	6
Financing activities	'	'
Credit facility borrowings, net	234	-106
Employee taxes paid in exchange for stock awards forfeited	-232	'
Issuance of common stock under employee stock plan	207	'
Proceeds from sale of common stock, preferred stock and warrants, net of issuance costs	5,837	'
Repurchase of common stock, net of issuance cost	'	-111
Net cash provided by (used in) financing activities	6,046	-217
Net decrease in cash and cash equivalents	-2,377	-6,071
Cash and cash equivalents at beginning of the period	12,098	15,877
Cash and cash equivalents at end of the period	$9,721	$9,806

Note_1_Basis_of_Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Basis of Accounting [Text Block]	'
	1.  Basis of Presentation
	The condensed consolidated balance sheet as of December 31, 2013, the condensed consolidated statements of operations for the three and nine months ended December 31, 2013 and 2012, and the condensed consolidated statements of cash flows for the nine months ended December 31, 2013 and 2012 have been prepared by the Company and are unaudited. In the opinion of management, all necessary adjustments (which include normal recurring adjustments) have been made to present fairly the financial position at December 31, 2013, and the results of operations and cash flows for the three and nine months ended December 31, 2013 and 2012, respectively. Interim results are not necessarily indicative of the results for a full fiscal year. The condensed consolidated balance sheet as of March 31, 2013 has been derived from the audited consolidated financial statements at that date.
	Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2013.
	The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Company’s condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2.  Summary of Significant Accounting Policies
	Other than the significant policies added below, there have been no material changes to any of the Company’s significant accounting policies and estimates as disclosed in the Company’s Annual Report on Form 10-K for the year ended March 31, 2013.
	Private Placement Funding with Redeemable Convertible Preferred Stock and Warrants
	On May 31, 2013, in connection with the first closing of a private placement equity financing (the “Financing”), the Company sold and issued 577,105 shares of our common stock (the “Common Shares”), and 231,518 shares of our newly created redeemable Series C Convertible Preferred Stock (the “Series C Stock”), to certain institutional funds and other accredited investors (“Outside Investors”) at a purchase price of $7.00 per share. The Series C Stock automatically converted into 231,518 shares of common stock upon stockholder approval at the annual meeting on September 10, 2013. Had the Series C Stock not converted into common stock, the Series C Stock would have been redeemable at the option of the holder and was therefore recorded in temporary equity until September 10, 2013. In addition, the Company issued to the Outside Investors Series A Warrants to purchase common stock as amended on September 4, 2013 (the “Series A Warrants”), initially exercisable for 404,309 shares of common stock. The exercise price of the Series A Warrants is $7.75 per share. The Series A Warrants have a five-year term and first became exercisable on November 30, 2013, six months following the date of issuance. Prior to amendment on September 4, 2013, the Series A Warrants had an exercise price of $8.75 per share and had a potential adjustment to the warrant exercise price that could result in the event we issued securities at a price below the then current exercise price. In addition, the amendment removed a cash settlement provision in the case of a Fundamental Transaction, as defined in the Warrant agreement.
	On September 12, 2013, in connection with the second closing (the “Second Closing”) of a private placement equity financing, the Company sold and issued 91,144 shares of its common stock at a purchase price per share of $7.00 to certain members of management and the Board of Directors of the Company (the “Second Closing Investors”). The $0.6 million aggregate gross purchase price was received in cash and recorded in stockholders’ equity.
	In addition, at the Second Closing the Company issued to each Second Closing Investor a Series B warrant to purchase common stock (the “Series B Warrants”), initially exercisable for 45,571 shares of common stock. The exercise price of the Series B Warrants is $7.75 per share. The warrants have a five-year term, and are not exercisable for the first six months following the date of issuance. The Company has evaluated the Series B Warrants issued in the Financing and has concluded that equity classification is appropriate as all such warrants are considered to be indexed to the Company’s equity and there are no settlement provisions that would result in classification as a debt instrument.
	In connection with the Financing, the Company issued to Lake Street Capital Markets, LLC, who served as the placement agent in the Financing, warrants to purchase an aggregate of 26,993 shares of common stock, which represents 3% of the total number of Common Shares and shares of Series C Stock sold in the Financing.
		(a)	Presentation of Series A Warrants
	Prior to amendment on September 4, 2013, the potential adjustment to the Series A Warrant exercise price precluded the warrants from meeting the criteria set forth in ASC 815-40, “Derivatives and Hedging – Contracts in Entity’s own Stock” to be considered indexed to the Company’s own stock. Accordingly, the fair value of the Series A Warrants was initially recorded as a liability. We estimated the fair value of these warrants at the May 31, 2013 issuance date using the Black-Scholes model and revalued the Series A Warrants as of June 30, 2013 and upon amendment on September 4, 2013 when the Series A Warrants were no longer required to be reported as a liability and were reclassified to equity using the September 4, 2013 Black-Sholes value of $1.3 million. The Black-Scholes model requires the input of highly subjective assumptions, including the warrant’s risk free rate and stock price volatility. The change in the fair value of the Series A Warrants was recognized in the statements of operations within non-operating income (expense).
		(b)	Presentation of Redeemable Convertible Preferred Stock
	Because the Series C Stock was redeemable at the option of the holder (had the stockholders not approved conversion on September 10, 2013 as discussed above), the Company recorded the Series C Stock in temporary equity until conversion on September 10, 2013 when the redemption value of $1.6 million was reclassified to stockholders’ equity.
		(c)	Beneficial Conversion Feature (“BCF”)
	The Series C Stock was assessed under ASC 470, “Debt,” and the Company determined that the conversion to common stock qualifies as a BCF since it had a nondetachable conversion feature that was in the money at the commitment date. The BCF computation compares the carrying value of the preferred stock after the value of any derivatives has been allocated from the proceeds (in this case, the warrant liability) to the transaction date value of the number of shares that the holder can convert into. The calculation resulted in a BCF of $0.8 million. The BCF was recorded in additional paid-in capital.
		(d)	Carrying Values
	The proceeds of the Financing were allocated first to the fair value of the warrants and then to the common stock and Series C Stock sold on a pro rata basis. The Company accreted the Series C Stock to its redemption value, which was $1.6 million based upon the 231,518 shares sold multiplied by the $7.00 per share redemption price. Accretion was calculated through September 10, 2013 the earliest possible redemption date.
	The following table shows the allocation of proceeds from the Outside Investors and carrying value of the Series C Stock which was reclassified to stockholders’ equity upon conversion to common stock on September 10, 2013 (in thousands, except per share amounts):
	Gross proceeds on May 31, 2013		$	5,660
	Fair value of warrants on May 31, 2013			(2,268	)
	Gross proceeds to allocate to common stock and Series C Stock		$	3,392
	Gross proceeds allocated to common shares sold		$	2,421
	Related transaction costs allocated			(313	)
	Net value allocated to common shares sold		$	2,108
	Gross proceeds allocated to Series C Stock sold on May 31, 2013		$	971
	Related transaction costs allocated			(125	)
	Net value allocated to Series C Stock sold prior to BCF			846
	Calculated BCF value			(846	)
	Accretion of Series C Stock through September 10, 2013			1,620
	Carrying value of Series C Stock recalssified upon conversion to common stock		$	1,620
	Capitalized Software
	The Company capitalizes software development costs related to software developed for external use in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed ("ASC 985-20") upon achieving technological feasibility of the related products. See Note 4 below for more discussion.

Note_3_Customer_Concentrations

Note 3 - Customer Concentrations	9 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	3. Customer Concentrations
	A limited number of customers have historically accounted for a substantial portion of the Company’s revenues.
	Customers who accounted for at least 10% of total revenues were as follows:
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
	Customer A		14	%		13	%		15	%		13	%
	Customers who accounted for at least 10% of gross accounts receivable were as follows:
		December 31,			December 31,
		2013			2012
	Customer B		24	%		10	%
	Customer C		14	%		11	%
	Customer D		*			11	%
	No Customers accounted for at least 10% of gross accounts receivable as of March 31, 2013.

Note_4_Capitalized_Software

Note 4 - Capitalized Software	9 Months Ended
	Dec. 31, 2013
Research and Development [Abstract]	'
Research, Development, and Computer Software Disclosure [Text Block]	'
	4.  Capitalized Software
	The Company capitalizes software development costs upon achieving technological feasibility of the related products. Software development costs incurred prior to achieving technological feasibility are charged to engineering and product development expense as incurred.
	Capitalized software will be amortized once the product is available for general release, using the straight-line method over the estimated useful lives of the assets, which is three years. The recoverability of capitalized software is evaluated for recoverability based on estimated future gross revenues reduced by the associated costs. If gross revenues were to be significantly less than estimated, the net realizable value of the capitalized software intended for sale would be impaired, which could result in the write-off of all or a portion of the unamortized balance of such capitalized software.
	Amortization expense was $0.01 million for the three months ended December 31, 2013 and is included in the product cost of revenue. Prior to the nine months ended December 31, 2013, these costs were not capitalized due to the short length of time between technological feasibility and general availability of software versions. The unamortized balance of capitalized software was $0.7 million as of December 31, 2013.

Note_5_Fair_Value_Measurements

Note 5 - Fair Value Measurements	9 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Fair Value, Measurement Inputs, Disclosure [Text Block]	'
	5. Fair Value Measurements
	In connection with the sale of common stock and its Series C Stock on May 31, 2013, the Company issued Series A Warrants which contained provisions for antidilution protection in the event that the Company issued other equity securities at a price below $8.75 per common share. Because of the potential adjustment to the warrant exercise price that could result from this anti-dilution protection, the warrants did not meet the criteria set forth in ASC 815-40, “Derivatives and Hedging – Contracts in Entity’s own Stock” to be considered indexed to the Company’s own stock.
	Accordingly, the Company recorded the fair value of these Series A Warrants as a liability as of June 30, 2013. The Company estimated the fair value of these warrants at the issuance date using the Black-Scholes Model. The Company characterized this warrant liability as a Level 3 liability because its fair value measurement was based, in part, on significant inputs not observed in the market and reflects the Company’s assumptions as to the expected warrant exercise price, the expected volatility of the Company’s common stock, the expected dividend yield, the expected term of the warrant instrument and the expected percentage of warrants to be exercised.
	As discussed in Note 2 above, the Series A Warrants were amended on September 4, 2013, which caused these warrants to be reclassified to equity using the September 4, 2013 Black-Sholes value and recognized the change in the fair value of the warrants in the statements of operations as other income (expense). The following assumptions and other inputs were used to compute the fair value of the warrant liability as of the May 31, 2013 issuance date, the June 30, 2013 quarter-end date and the September 4, 2013 amendment date as shown below:
		September 4,			May 31,			June 30,
		2013			2013			2013
	Common stock price	$	5.49		$	8.6		$	9
	Expected warrant exercise price	$	7.75		$	8.75		$	8.75
	Remaining term of warrant (years)		4.75			5			4.92
	Expected volatility		76.7	%		76	%		76	%
	Average risk free interest rate		1.74	%		1.05	%		1.41	%
	Expected dividend yield		-			-			-
	Changes in the warrant liability from May 31, 2013 to December 31, 2013 were as follows:
	Balance, May 31, 2013	$	2,268
	Increase in fair value		139
	Balance, June 30, 2013	$	2,407
	Decrease in fair value		(1,121	)
	Balance, September 4, 2013	$	1,286
	Reclassification to equity		(1,286	)
	Balance, September 30, and December 31, 2013	$	-

Note_6_Segment_and_Geographic_

Note 6 - Segment and Geographic Information	21 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	6.  Segment and Geographic Information
	The Company operates as one business segment and therefore segment information is not presented.
	International revenues are attributable to countries based on the location of the customers. For the three and nine months ended December 31, 2013 and 2012, sales to international locations were derived primarily from Canada, India, New Zealand, Switzerland and the United Kingdom.
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
	International revenues		9	%		16	%		11	%		12	%
	Domestic revenues		91	%		84	%		89	%		88	%
	Total revenues		100	%		100	%		100	%		100	%
	As of December 31, 2013 and March 31, 2013, the Company held long-lived assets outside of the United States with a net book value of approximately $0.1 million in each period. These assets were located in Odessa, Ukraine.

Note_7_Credit_Facility

Note 7 - Credit Facility	9 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	7.   Credit Facility
	On September 29, 2011, the Company entered into a Business Financing Agreement with Bridge Bank, National Association, which was modified during fiscal 2013 (as amended, the “Credit Facility”).  The Credit Facility provides a revolving receivables financing facility in an amount up to $3.0 million (the “Receivables Financing Facility”) and a revolving cash secured financing facility in an amount up to $4.0 million (the “Working Capital Facility”), for an aggregate revolving credit facility of up to $7.0 million.
	The Receivables Financing Facility may be drawn in amounts up to $3.0 million in the aggregate, subject to a minimum borrowing base requirement equal to 80% of the Company’s eligible accounts receivable as determined under the Credit Facility. The Working Capital Facility may be drawn in such amounts as requested by the Company, not to exceed $4.0 million in the aggregate. The Credit Facility terminates on February 20, 2014, provided, however, that in the event of an early termination by the Company, a penalty of 1.0% of the total credit facility would be triggered.
	All amounts borrowed under the Credit Facility are secured by a general security interest on the assets of the Company and are subject to a 1.75 Current Ratio of (i) cash and cash equivalents plus all eligible receivables in relation to (ii) the Company’s current liabilities excluding current deferred revenue.
	Except as otherwise set forth in the Credit Facility, borrowings made under the Receivables Financing Facility will bear interest at a rate equal to the prime rate or 3.25%, whichever is greater, plus 0.25%, and borrowings made under the Working Capital Facility will bear interest at a rate equal to the financial institution’s certificate of deposit 30-day rate plus 200 basis points, with the total minimum monthly interest to be charged being $2,000.
	As of December 31, 2013 and March 31, 2013, the Company owed $6.2 million and $6.0 million, respectively, under the Credit Facility, and no amounts were available for future borrowings.

Note_8_Restructuring

Note 8 - Restructuring	9 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring and Related Activities Disclosure [Text Block]	'
	8.   Restructuring
	During the second quarter of fiscal 2014, the Company initiated a restructuring plan to reorganize its operations. The Company incurred $0.2 million in severance costs under this plan, all of which is being paid in fiscal 2014.
	During the fourth quarter of fiscal 2013, the Company initiated a restructuring plan to reorganize its operations in-line with its conversion to a SaaS model. The Company incurred $0.3 million in severance costs under this plan, of which $0.1 million was paid in fiscal 2013 and $0.2 million was paid during the first nine months of fiscal 2014.
	The following table summarizes changes in the Company’s restructuring liability during the nine months ended December 31, 2013:
		Fiscal 2013			Fiscal 2014
		Restructuring Plan			Restructuring Plan
		(in thousands)
	Balance as of March 31, 2013	$	232		$	-
	New charges		-			227
	Cash paid		(232	)		(178	)
	Balance as of December 31, 2013	$	-		$	49

Note_9_Commitments_and_Conting

Note 9 - Commitments and Contingencies	9 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	9.  Commitments and Contingencies
	From time to time the Company is subject to certain routine legal proceedings, as well as demands, claims and threatened litigation, that arise in the normal course of its business. The Company believes that the ultimate amount of liability, if any, for any pending claims of any type (either alone or combined) will not materially affect its financial position, results of operations or liquidity.
	The Company has a lease commitment for its office space which expires in December 2014. Total payments subsequent to December 31, 2013 through December 2014 are expected to be $0.3 million.

Note_10_Redeemable_Convertible

Note 10 - Redeemable Convertible Preferred Stock and Warrants	9 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Preferred Stock [Text Block]	'
	10.  Redeemable Convertible Preferred Stock and Warrants
	Series C Stock
	As disclosed in Note 2 Summary of Significant Accounting Policies, on May 31, 2013, the Company sold and issued 577,105 Common Shares and 231,518 shares of Series C Stock to Outside Investors at a purchase price of $7.00 per share in its first closing of the Financing. Following stockholder approval on September 10, 2013, the Series C Stock was converted into 231,528 shares of common stock.
	Warrants
	In addition to the issuance of the Common Shares and Series C Stock, at the first closing of the Financing the Company issued to the Outside Investors the Series A Warrants initially exercisable for 404,309 shares of common stock. On September 12, 2013, at the Second Closing, the Company sold and issued 91,144 Common Shares to the Second Closing Investors and issued the Series B Warrants, initially exercisable for 45,571 shares of common stock. The exercise price of the Series A Warrants and Series B Warrants is $7.75 per share. The Series A Warrants and Series B Warrants have a five-year term and are not exercisable for the first six months following the date of issuance.

Note_11_StockBased_Compensatio

Note 11 - Stock-Based Compensation	9 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	11.  Stock-Based Compensation
	Equity Incentive Program
	The Company’s equity incentive program is a broad-based, retention program comprised of stock options, restricted stock units and an employee stock purchase plan designed to align stockholder and employee interests. For a description of the Company’s equity plans, see the notes to consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended March 31, 2013.
	The Company granted the following stock options and restricted units:
			Three Months Ended								Nine Months Ended
			December 31,								December 31,
			2013				2012				2013				2012
			(in thousands)								(in thousands)
	Stock Options			216				-				266				-
	Restricted Stock Units			261				449				472				623
	Total Granted			477				449				738				623
	Valuation Assumptions
	The Company did not issue employee stock options during the three or nine months ended December 31, 2012. For the three months ended December 31, 2013, the Company calculated the fair value of its employee stock options at the date of grant with the following weighted average assumptions:
			Period Ended
			31-Dec
			Three Months				Nine Months
	Risk-free interest rate			0.91	%			0.88	%
	Dividend yield			0	%			0	%
	Expected volatility			58.21	%			58.43	%
	Expected term in years			3.21				3.21
	Weighted average fair value at grant date		$	2.56			$	2.52
	The following table summarizes activity under the equity incentive plans for the indicated periods:
							Options and Restricted Stock Units Outstanding
			Shares available for grant				Number of shares				Weighted average exercise price
				(in thousands except for per share amount)
	Outstanding at September 30, 2013			844				618			$	6.97
	Restricted stock units granted			(261	)			261
	Restricted stock units released			-				(48	)
	Restricted stock units cancelled			83				(83	)
	Options granted*			(216	)			216			$	6.28
	Options granted outside of plan*			187				-
	Options exercised			-				(18	)		$	5.42
	Options cancelled			21				(21	)		$	10.28
	Outstanding at December 31, 2013			658				925			$	6.41
	*includes 186,979 shares granted to Mr. Blaine Mathieu as part of his employment agreement. For more information refer to Footnote 16.
	The weighted average remaining contractual term for exercisable options is 6.2 years. The intrinsic value is calculated as the difference between the market value as of December 31, 2013 and the exercise price of the shares. The market value of the Company’s common stock as of December 31, 2013 was $6.41 as reported by the NASDAQ Capital Market. The aggregate intrinsic value of stock options outstanding at December 31, 2013 and 2012 was $100,000 and $200,000, respectively. The aggregate intrinsic value of restricted stock units outstanding at December 31, 2013 and 2012 was $3.7 million and $4.7 million, respectively.
	The options outstanding and exercisable at December 31, 2013 were in the following exercise price ranges:
						Options Outstanding								Options Vested
	Range of Exercise Prices per share					Number of Shares (in thousands)				Weighted-Average Remaining Contractual Life (in years)				Number of Shares				Weighted-Average Exercise Price per share
	$3.70	—	$5.72				109				8.16				51			$	5.18
	$5.93	-	$5.93				-				0.18				-				5.93
	$6.28	—	$6.28				187				9.92				-				-
	$6.30	—	$31.30				44				7.77				15				13.05
	$34.00	—	$34.00				2				1.05				2				34
	$3.70	—	$34.00				342				9.03				68			$	7.57
	The effect of recording stock-based compensation expense (including expense related to the ESPP discussed below) for each of the periods presented was as follows (in thousands):
			Three Months Ended									Nine Months Ended
			December 31,									December 31,
			2013				2012					2013				2012
			(in thousands)									(in thousands)
	Cost of revenues		$	76			$	32				$	191				89
	Research and development			43				39					131				113
	Sales and marketing			108				93					238				199
	General and administrative			239				174					361				298
	Impact on net loss		$	466			$	338				$	921			$	699
	Based upon the departures of our CEO and COO in August 2013, stock-compensation expense for shares not yet earned under an executive performance grant was reversed, creating negative expense of $0.5 million for the quarter ended September 30, 2013. As of December 31, 2013, the unrecorded share-based compensation balance related to stock options and restricted stock units outstanding excluding estimated forfeitures was $2.7 million and will be recognized over an estimated weighted average amortization period of 3.1 years. The amortization period is based on the expected remaining vesting term of the options and restricted stock units.
	1999 Employee Stock Purchase Plan (“ESPP”)
	The price paid for the Company’s common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the Company’s common stock at the beginning of each offering period or at the end of each offering period. The compensation expense in connection with the ESPP for the three and nine months ended December 31, 2013 was $19,000 and $115,000, respectively. The Company did not have ESPP expense during the three and nine months ended December 31, 2012. During the nine months ended December 31, 2013 there were 28,901 shares issued under the ESPP. There were no shares issued under the ESPP during the nine months ended December 31, 2012.
	For the three months ended December 31, 2013, the Company calculated the fair value of rights granted under its employee stock purchase plan at the date of grant using the following weighted average assumptions:
			Period Ended
			December 31,
			Three Months				Nine Months
	Risk-free interest rate			0.04	%			0.08	%
Dividend yield			0	%			0	%
Expected volatility			61.9	%			59.4	%
Expected term in years			0.5				0.5
Weighted average fair value at grant date		$	2.74			$	2.86

Note_12_Comprehensive_Settleme

Note 12 - Comprehensive Settlement Agreement (Comprehensive Settlement Agreement [Member])	9 Months Ended
	Dec. 31, 2013
Comprehensive Settlement Agreement [Member]	'
Note 12 - Comprehensive Settlement Agreement [Line Items]	'
Legal Matters and Contingencies [Text Block]	'
	12. Comprehensive Settlement Agreement
	Pursuant to a Comprehensive Settlement Agreement between the Company and Versata (“Settlement Agreement”), during fiscal 2012, the Company paid to Versata the following: (i) $4.5 million for the repayment of all outstanding amounts payable under the 2007 Settlement Agreement, (ii) $472,000 for the repurchase of the Company common stock held by Versata and (iii) $500,000 for the consulting services to be provided by Versata’s affiliated entity, with an additional $500,000 of consulting services provided during the three months ended December 31, 2012, which resulted in a $500,000 charge during that period for consulting services paid as required by the Settlement Agreement.

Note_13_Income_Taxes

Note 13 - Income Taxes	9 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	13.  Income Taxes
	At December 31, 2013, the Company had approximately $2.1 million of unrecognized tax benefits. As these unrecognized tax benefits relate to deferred tax assets with a full valuation allowance, there will be no effect on the Company’s effective tax rate if these amounts are recognized.
	The Company’s Federal, state, and foreign tax returns may be subject to examination by the tax authorities from fiscal years 1998 to 2013 due to net operating losses and tax carryforwards unutilized from such years.

Note_14_Computation_of_Basic_a

Note 14 - Computation of Basic and Diluted Net Loss per Share	9 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	14.  Computation of Basic and Diluted Net Loss per Share
	Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period.
	The Company excludes securities from its diluted net loss per share computation when their effect would be antidilutive to net loss per share amounts. The following common stock equivalents were excluded from the net loss per share computation:
		Three Months Ended				Nine Months Ended
		December 31,				December 31,
		2013		2012		2013		2012
		(in thousands)				(in thousands)
	Options		145		45		71		-
	Unvested restricted stock units		21		443		23		275
	Warrants		432		-		290		-
	Total common stock equivalents excluded from diluted net loss per common share
			598		488		384		275

Note_15_Recent_Accounting_Pron

Note 15 - Recent Accounting Pronouncements	9 Months Ended
	Dec. 31, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	'
	15.  Recent Accounting Pronouncements
	The Company did not adopt any new pronouncements during the quarter ended December 31, 2013.

Note_16_Other_Events

Note 16 - Other Events	9 Months Ended
	Dec. 31, 2013
Other Events [Abstract]	'
Other Events [Text Block]	'
	16.  Other Events
	New CEO Employment Agreement
	On December 4, 2013, the Company’s Board of Directors appointed Mr. Blaine Mathieu as President and Chief Executive Officer of the Company and as a member of its Board and the Company entered into an employment offer letter and a severance agreement with Mr. Mathieu. The employment offer letter provides for an annual salary of $300,000 and an annual target incentive bonus in the amount of $150,000, subject to the achievement of annual performance milestones established by the Board of Directors or the Board’s Compensation Committee. Mr. Mathieu was also granted a non-qualified option to purchase 186,979 shares of the Company’s common stock, exercisable for 10 years, subject to vesting over a 48-month period, with one quarter (1/4) of the option shares vesting after 12 months of continuous service from Mr. Mathieu’s start date, and the remaining option shares vesting in equal monthly installments over the following 36 months of continuous service to the Company. Under the terms of his severance agreement, the option shares would vest in full if Mr. Mathieu’s service to the Company is terminated by the Company without Cause or by him for Good Reason within 12 months following a Change in Control (as each term is defined in Mr. Mathieu’s severance agreement). The option was granted as an inducement grant outside of the Company’s 1999 Equity Incentive Plan in reliance on NASDAQ Listing Rule 5635(c)(4).

Note_17_Subsequent_Events

Note 17 - Subsequent Events	9 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	17.  Subsequent Events
	Purchase Agreement
	On January 24, 2014, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with certain institutional funds and other accredited investors pursuant to which the Company sold and issued 765,605 shares of its common stock at a price of $6.00 per share, and 68,047.0 shares of Series D Convertible Preferred Stock at a price of $60.00 per share, raising aggregate proceeds of approximately $8.7 million (the “2014 Financing”). The proceeds raised in the 2014 Financing resulted in the Company having stockholders’ equity above the $2.5 million minimum required by the NASDAQ Stock Market, and as such, the Company believes that as of the date of this quarterly report on Form 10-Q, it has raised the funds necessary to regain compliance with NASDAQ’s stockholders’ equity requirement.
	Filing of Certificate of Designations for Series D Preferred Stock
	Pursuant to the Certificate of Designations, Preferences and Rights of Series D Convertible Preferred Stock filed by the Company with the Delaware Secretary of State on January 23, 2014, after stockholder approval, each whole share of Series D Preferred Stock will convert automatically into ten shares of common stock at an initial conversion price of $6.00 per share of common stock. The conversion price of the Series D Preferred Stock is subject to broad-based weighted-average anti-dilution adjustment in the event the Company issues securities, other than certain excepted issuances and subject to certain limitations, at a price below the then current conversion price.
	The Series D Preferred Stock is not entitled to a liquidation or dividend preference. Beginning on April 15, 2014, the Series D Preferred Stock is entitled to 10% accruing dividends per annum. The dividends are payable quarterly in cash, beginning on June 30, 2014. Beginning on January 24, 2015, the shares of Series D Preferred Stock shall be redeemed by the Company upon the request of the holders of at least a majority of the then outstanding Series D Preferred Stock, to the extent funds are legally available for such redemption. The redemption price shall be equal to the product of (i) the number of shares or fraction of a share of Series D Preferred Stock to be redeemed from each such holder multiplied by (ii) ten (10) times the conversion price then in effect, plus any accrued and unpaid dividends up to, but not including, the redemption date.
	The holders of Series D Preferred Stock have the right to vote together with the holders of the Company’s common stock as a single class on any matter on which the holders of common stock are entitled to vote, except that the holders of Series D Preferred Stock are not eligible to vote their shares of Series D Preferred Stock on the proposal to be submitted to the Company’s stockholders for approval of the issuance and sale of the securities in the 2014 Financing and the conversion of the Series D Preferred Stock. Holders of Series D Preferred Stock are entitled to cast a fraction of one vote for each share of common stock that would be issuable to such holder on the record date for the determination of stockholders entitled to vote at a conversion rate the numerator of which is $60.00 (as may be adjusted for any subdivision by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or similar event occurring prior to such record date) and the denominator of which is the closing bid price per share of the Common Stock on January 24, 2014, as reported by Bloomberg Financial Markets.
	Warrants
	In addition to the issuance of the shares of common stock and Series D Preferred Stock, the Company issued to each investor in the 2014 Financing a Warrant to purchase shares of common stock (the “Warrants”), initially exercisable for an aggregate of 723,030 shares of common stock. The exercise price of the Warrants is $7.00 per share. The Warrants have a five-year term, are not exercisable for the first six months following the date of issuance and include a cashless exercise provision which is only applicable if the common stock underlying the Warrants is not subject to an effective registration statement or otherwise cannot be sold without restriction pursuant to SEC Rule 144.
	The Company has evaluated the Warrants issued in the 2014 Financing and has concluded that equity classification is appropriate as all such Warrants are considered to be indexed to the Company’s equity and there are no settlement provisions that would result in classification as a debt instrument.
	In connection with the 2014 Financing, the Company issued to Lake Street Capital Markets, LLC, who served as the placement agent in the 2014 Financing, 11,029 shares of common stock, 980.4 shares of Series D Preferred Stock, and a warrant to purchase 10,416 shares of common stock, which represents approximately 1% of the total number of shares of common stock and Series D Preferred Stock sold in the 2014 Financing.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	'
	Private Placement Funding with Redeemable Convertible Preferred Stock and Warrants
	On May 31, 2013, in connection with the first closing of a private placement equity financing (the “Financing”), the Company sold and issued 577,105 shares of our common stock (the “Common Shares”), and 231,518 shares of our newly created redeemable Series C Convertible Preferred Stock (the “Series C Stock”), to certain institutional funds and other accredited investors (“Outside Investors”) at a purchase price of $7.00 per share. The Series C Stock automatically converted into 231,518 shares of common stock upon stockholder approval at the annual meeting on September 10, 2013. Had the Series C Stock not converted into common stock, the Series C Stock would have been redeemable at the option of the holder and was therefore recorded in temporary equity until September 10, 2013. In addition, the Company issued to the Outside Investors Series A Warrants to purchase common stock as amended on September 4, 2013 (the “Series A Warrants”), initially exercisable for 404,309 shares of common stock. The exercise price of the Series A Warrants is $7.75 per share. The Series A Warrants have a five-year term and first became exercisable on November 30, 2013, six months following the date of issuance. Prior to amendment on September 4, 2013, the Series A Warrants had an exercise price of $8.75 per share and had a potential adjustment to the warrant exercise price that could result in the event we issued securities at a price below the then current exercise price. In addition, the amendment removed a cash settlement provision in the case of a Fundamental Transaction, as defined in the Warrant agreement.
	On September 12, 2013, in connection with the second closing (the “Second Closing”) of a private placement equity financing, the Company sold and issued 91,144 shares of its common stock at a purchase price per share of $7.00 to certain members of management and the Board of Directors of the Company (the “Second Closing Investors”). The $0.6 million aggregate gross purchase price was received in cash and recorded in stockholders’ equity.
	In addition, at the Second Closing the Company issued to each Second Closing Investor a Series B warrant to purchase common stock (the “Series B Warrants”), initially exercisable for 45,571 shares of common stock. The exercise price of the Series B Warrants is $7.75 per share. The warrants have a five-year term, and are not exercisable for the first six months following the date of issuance. The Company has evaluated the Series B Warrants issued in the Financing and has concluded that equity classification is appropriate as all such warrants are considered to be indexed to the Company’s equity and there are no settlement provisions that would result in classification as a debt instrument.
	In connection with the Financing, the Company issued to Lake Street Capital Markets, LLC, who served as the placement agent in the Financing, warrants to purchase an aggregate of 26,993 shares of common stock, which represents 3% of the total number of Common Shares and shares of Series C Stock sold in the Financing.
		(a)	Presentation of Series A Warrants
	Prior to amendment on September 4, 2013, the potential adjustment to the Series A Warrant exercise price precluded the warrants from meeting the criteria set forth in ASC 815-40, “Derivatives and Hedging – Contracts in Entity’s own Stock” to be considered indexed to the Company’s own stock. Accordingly, the fair value of the Series A Warrants was initially recorded as a liability. We estimated the fair value of these warrants at the May 31, 2013 issuance date using the Black-Scholes model and revalued the Series A Warrants as of June 30, 2013 and upon amendment on September 4, 2013 when the Series A Warrants were no longer required to be reported as a liability and were reclassified to equity using the September 4, 2013 Black-Sholes value of $1.3 million. The Black-Scholes model requires the input of highly subjective assumptions, including the warrant’s risk free rate and stock price volatility. The change in the fair value of the Series A Warrants was recognized in the statements of operations within non-operating income (expense).
		(b)	Presentation of Redeemable Convertible Preferred Stock
	Because the Series C Stock was redeemable at the option of the holder (had the stockholders not approved conversion on September 10, 2013 as discussed above), the Company recorded the Series C Stock in temporary equity until conversion on September 10, 2013 when the redemption value of $1.6 million was reclassified to stockholders’ equity.
		(c)	Beneficial Conversion Feature (“BCF”)
	The Series C Stock was assessed under ASC 470, “Debt,” and the Company determined that the conversion to common stock qualifies as a BCF since it had a nondetachable conversion feature that was in the money at the commitment date. The BCF computation compares the carrying value of the preferred stock after the value of any derivatives has been allocated from the proceeds (in this case, the warrant liability) to the transaction date value of the number of shares that the holder can convert into. The calculation resulted in a BCF of $0.8 million. The BCF was recorded in additional paid-in capital.
		(d)	Carrying Values
	The proceeds of the Financing were allocated first to the fair value of the warrants and then to the common stock and Series C Stock sold on a pro rata basis. The Company accreted the Series C Stock to its redemption value, which was $1.6 million based upon the 231,518 shares sold multiplied by the $7.00 per share redemption price. Accretion was calculated through September 10, 2013 the earliest possible redemption date.
	The following table shows the allocation of proceeds from the Outside Investors and carrying value of the Series C Stock which was reclassified to stockholders’ equity upon conversion to common stock on September 10, 2013 (in thousands, except per share amounts):
	Gross proceeds on May 31, 2013		$	5,660
	Fair value of warrants on May 31, 2013			(2,268	)
	Gross proceeds to allocate to common stock and Series C Stock		$	3,392
	Gross proceeds allocated to common shares sold		$	2,421
	Related transaction costs allocated			(313	)
	Net value allocated to common shares sold		$	2,108
	Gross proceeds allocated to Series C Stock sold on May 31, 2013		$	971
	Related transaction costs allocated			(125	)
	Net value allocated to Series C Stock sold prior to BCF			846
	Calculated BCF value			(846	)
	Accretion of Series C Stock through September 10, 2013			1,620
	Carrying value of Series C Stock recalssified upon conversion to common stock		$	1,620
Capitalization of Internal Costs, Policy [Policy Text Block]	'
	Capitalized Software
	The Company capitalizes software development costs related to software developed for external use in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed ("ASC 985-20") upon achieving technological feasibility of the related products. See Note 4 below for more discussion.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Stock by Class [Table Text Block]	'
	Gross proceeds on May 31, 2013	$	5,660
	Fair value of warrants on May 31, 2013		(2,268	)
	Gross proceeds to allocate to common stock and Series C Stock	$	3,392
	Gross proceeds allocated to common shares sold	$	2,421
	Related transaction costs allocated		(313	)
	Net value allocated to common shares sold	$	2,108
	Gross proceeds allocated to Series C Stock sold on May 31, 2013	$	971
	Related transaction costs allocated		(125	)
	Net value allocated to Series C Stock sold prior to BCF		846
	Calculated BCF value		(846	)
	Accretion of Series C Stock through September 10, 2013		1,620
	Carrying value of Series C Stock recalssified upon conversion to common stock	$	1,620

Note_3_Customer_Concentrations1

Note 3 - Customer Concentrations (Tables)	9 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
	Customer A		14	%		13	%		15	%		13	%
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
		December 31,			December 31,
		2013			2012
	Customer B		24	%		10	%
	Customer C		14	%		11	%
	Customer D		*			11	%

Note_5_Fair_Value_Measurements1

Note 5 - Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		September 4,			May 31,			June 30,
		2013			2013			2013
	Common stock price	$	5.49		$	8.6		$	9
	Expected warrant exercise price	$	7.75		$	8.75		$	8.75
	Remaining term of warrant (years)		4.75			5			4.92
	Expected volatility		76.7	%		76	%		76	%
	Average risk free interest rate		1.74	%		1.05	%		1.41	%
	Expected dividend yield		-			-			-
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	Balance, May 31, 2013	$	2,268
	Increase in fair value		139
	Balance, June 30, 2013	$	2,407
	Decrease in fair value		(1,121	)
	Balance, September 4, 2013	$	1,286
	Reclassification to equity		(1,286	)
	Balance, September 30, and December 31, 2013	$	-

Note_6_Segment_and_Geographic_1

Note 6 - Segment and Geographic Information (Tables)	9 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
	International revenues		9	%		16	%		11	%		12	%
	Domestic revenues		91	%		84	%		89	%		88	%
	Total revenues		100	%		100	%		100	%		100	%

Note_8_Restructuring_Tables

Note 8 - Restructuring (Tables)	9 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring and Related Costs [Table Text Block]	'
		Fiscal 2013			Fiscal 2014
		Restructuring Plan			Restructuring Plan
		(in thousands)
	Balance as of March 31, 2013	$	232		$	-
	New charges		-			227
	Cash paid		(232	)		(178	)
	Balance as of December 31, 2013	$	-		$	49

Note_11_StockBased_Compensatio1

Note 11 - Stock-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2013
Note 11 - Stock-Based Compensation (Tables) [Line Items]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
							Options and Restricted Stock Units Outstanding
			Shares available for grant				Number of shares				Weighted average exercise price
				(in thousands except for per share amount)
	Outstanding at September 30, 2013			844				618			$	6.97
	Restricted stock units granted			(261	)			261
	Restricted stock units released			-				(48	)
	Restricted stock units cancelled			83				(83	)
	Options granted*			(216	)			216			$	6.28
	Options granted outside of plan*			187				-
	Options exercised			-				(18	)		$	5.42
	Options cancelled			21				(21	)		$	10.28
	Outstanding at December 31, 2013			658				925			$	6.41
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	'
			Period Ended
			31-Dec
			Three Months				Nine Months
	Risk-free interest rate			0.91	%			0.88	%
	Dividend yield			0	%			0	%
	Expected volatility			58.21	%			58.43	%
	Expected term in years			3.21				3.21
	Weighted average fair value at grant date		$	2.56			$	2.52
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
						Options Outstanding								Options Vested
	Range of Exercise Prices per share					Number of Shares (in thousands)				Weighted-Average Remaining Contractual Life (in years)				Number of Shares				Weighted-Average Exercise Price per share
	$3.70	—	$5.72				109				8.16				51			$	5.18
	$5.93	-	$5.93				-				0.18				-				5.93
	$6.28	—	$6.28				187				9.92				-				-
	$6.30	—	$31.30				44				7.77				15				13.05
	$34.00	—	$34.00				2				1.05				2				34
	$3.70	—	$34.00				342				9.03				68			$	7.57
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
			Three Months Ended									Nine Months Ended
			December 31,									December 31,
			2013				2012					2013				2012
			(in thousands)									(in thousands)
	Cost of revenues		$	76			$	32				$	191				89
	Research and development			43				39					131				113
	Sales and marketing			108				93					238				199
	General and administrative			239				174					361				298
	Impact on net loss		$	466			$	338				$	921			$	699
Stock Options and Restricted Units [Member]	'
Note 11 - Stock-Based Compensation (Tables) [Line Items]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
			Three Months Ended								Nine Months Ended
			December 31,								December 31,
			2013				2012				2013				2012
			(in thousands)								(in thousands)
	Stock Options			216				-				266				-
	Restricted Stock Units			261				449				472				623
	Total Granted			477				449				738				623
ESPP [Member]	'
Note 11 - Stock-Based Compensation (Tables) [Line Items]	'
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	'
			Period Ended
			December 31,
			Three Months				Nine Months
	Risk-free interest rate			0.04	%			0.08	%
	Dividend yield			0	%			0	%
	Expected volatility			61.9	%			59.4	%
	Expected term in years			0.5				0.5
	Weighted average fair value at grant date		$	2.74			$	2.86

Note_14_Computation_of_Basic_a1

Note 14 - Computation of Basic and Diluted Net Loss per Share (Tables)	9 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		Three Months Ended				Nine Months Ended
		December 31,				December 31,
		2013		2012		2013		2012
		(in thousands)				(in thousands)
	Options		145		45		71		-
	Unvested restricted stock units		21		443		23		275
	Warrants		432		-		290		-
	Total common stock equivalents excluded from diluted net loss per common share
			598		488		384		275

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

Sep. 12, 2013

Sep. 10, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 04, 2013

Sep. 12, 2013

31-May-13

Sep. 04, 2013

Sep. 12, 2013

Sep. 12, 2013

Sep. 12, 2013

Sep. 12, 2013

Sep. 12, 2013

Sep. 10, 2013

31-May-13

31-May-13

31-May-13

Sep. 12, 2013

Sep. 12, 2013

Sep. 03, 2013

Sep. 10, 2013

31-May-13

Series A Warrant (Member)

Series A Warrant (Member)

Series A Warrant (Member)

Series A Warrant (Member)

Series A Warrant (Member)

Series B Warrant (Member)

Series B Warrant (Member)

Series B Warrant (Member)

Series B Warrant (Member)

Series B Warrant (Member)

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Second Closing (Member)

Second Closing (Member)

Lake Street Capital Markets, LLC [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Purchase Agreement (Member)

First Closing (Member)

Second Closing (Member)

Second Closing (Member)

Lake Street Capital Markets, LLC [Member]

Second Closing (Member)

Second Closing (Member)

Purchase Agreement (Member)

Purchase Agreement (Member)

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

577,105

'

91,144

91,144

'

231,518

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

231,528

231,518

'

'

'

'

'

'

'

Sale of Stock, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7

$7

$7

'

'

'

Conversion of Stock, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

231,518

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

404,309

'

404,309

'

'

'

45,571

45,571

26,993

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

7.75

7.75

'

'

7.75

7.75

'

'

'

'

'

'

'

'

'

8.75

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms

'5 years

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance or Sale of Equity (in Dollars)

'

'

$5,837,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$600,000

'

'

$971,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value (in Dollars)

'

'

'

'

'

'

'

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars)

'

846,000

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Redemption Amount (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,600,000

'

Preferred Stock, Redemption Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7

'

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Carrying Value of the Series C Stock (USD $)	3 Months Ended	9 Months Ended				0 Months Ended
In Thousands, unless otherwise specified	Sep. 10, 2013	Dec. 31, 2013	Sep. 04, 2013	Jun. 30, 2013	31-May-13	31-May-13	31-May-13	31-May-13	31-May-13	Sep. 10, 2013
						Common Stock, Series C Stock and Warrants [Member]	Common Stock and Series C Stock [Member]	Common Shares [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'
Proceeds from issuance of equity	'	$5,837	'	'	'	$5,660	$3,392	$2,421	$971	'
Related transaction costs allocated	'	'	'	'	'	'	'	-313	-125	'
Net value allocated to shares sold	'	'	'	'	'	'	'	2,108	846	'
Calculated BCF value	-846	-800	'	'	'	'	'	'	'	'
Accretion of Series C Stock through September 10, 2013	1,620	1,621	'	'	'	'	'	'	'	'
Carrying value of Series C Stock recalssified upon conversion to common stock	'	'	'	'	'	'	'	'	'	1,620
Fair value of warrants on May 31, 2013	'	'	($1,286)	($2,407)	($2,268)	'	'	'	'	'

Note_3_Customer_Concentrations2

Note 3 - Customer Concentrations (Details) (Accounts Receivable [Member])	12 Months Ended
	Mar. 31, 2013
Accounts Receivable [Member]	'
Note 3 - Customer Concentrations (Details) [Line Items]	'
Number of Customers for Concentration Risk	0
Concentration Risk, Percentage	10.00%

Note_3_Customer_Concentrations3

Note 3 - Customer Concentrations (Details) - Major Customers by Revenues (Customer A [Member], Sales Revenue, Net [Member])	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Customer A [Member] | Sales Revenue, Net [Member]	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'
Customer A	14.00%	13.00%	15.00%	13.00%

Note_3_Customer_Concentrations4

Note 3 - Customer Concentrations (Details) - Major Customers by Accounts Receivable (Accounts Receivable [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Mar. 31, 2013
	Customer B [Member]	Customer B [Member]	Customer C [Member]	Customer C [Member]	Customer D [Member]
Concentration Risk [Line Items]	'	'	'	'	'	'
Customer	24.00%	10.00%	14.00%	11.00%	11.00%	10.00%

Note_4_Capitalized_Software_De

Note 4 - Capitalized Software (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Note 4 - Capitalized Software (Details) [Line Items]	'
Capitalized Computer Software, Amortization	$0.01
Unamortized Balance of Capitalized Software	$0.70
Computer Software, Intangible Asset [Member]	'
Note 4 - Capitalized Software (Details) [Line Items]	'
Finite-Lived Intangible Asset, Useful Life	'3 years

Note_5_Fair_Value_Measurements2

Note 5 - Fair Value Measurements (Details) (USD $)	31-May-13
Disclosure Text Block [Abstract]	'
Shares Issued, Price Per Share	$8.75

Note_5_Fair_Value_Measurements3

Note 5 - Fair Value Measurements (Details) - Valuation Assumptions (USD $)	3 Months Ended				9 Months Ended
	Dec. 31, 2013	Sep. 04, 2013	Jun. 30, 2013	31-May-13	Dec. 31, 2013
Valuation Assumptions [Abstract]	'	'	'	'	'
Common stock price (in Dollars per share)	$6.41	$5.49	$9	$8.60	$6.41
Expected warrant exercise price (in Dollars per share)	'	$7.75	$8.75	$8.75	'
Remaining term of warrant (years)	'	'4 years 9 months	'4 years 335 days	'5 years	'
Expected volatility	58.21%	76.70%	76.00%	76.00%	58.43%
Average risk free interest rate	0.91%	1.74%	1.41%	1.05%	0.88%

Note_5_Fair_Value_Measurements4

Note 5 - Fair Value Measurements (Details) - Changes in the Warrant Liability (USD $)	1 Months Ended	2 Months Ended	4 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	Sep. 04, 2013	Dec. 31, 2013	Dec. 31, 2013	31-May-13
Changes in the Warrant Liability [Abstract]	'	'	'	'	'
Balance warrant liability	$2,407	$1,286	'	'	$2,268
Reclassification to equity	'	'	-1,286	'	'
Decrease in fair value	139	-1,121	'	-982	'
Increase in fair value	$139	($1,121)	'	($982)	'

Note_6_Segment_and_Geographic_2

Note 6 - Segment and Geographic Information (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Mar. 31, 2013
Segment Reporting [Abstract]	'	'
Number of Reportable Segments	1	'
Long-Lived Assets	$0.10	$0.10

Note_6_Segment_and_Geographic_3

Note 6 - Segment and Geographic Information (Details) - Revenues from External Customers Attributed to Foreign Countries by Geographic Area	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers Attributed to Foreign Countries by Geographic Area [Abstract]	'	'	'	'
International revenues	9.00%	16.00%	11.00%	12.00%
Domestic revenues	91.00%	84.00%	89.00%	88.00%
Total revenues	100.00%	100.00%	100.00%	100.00%

Note_7_Credit_Facility_Details

Note 7 - Credit Facility (Details) (USD $)	9 Months Ended
	Dec. 31, 2013	Mar. 31, 2013
Note 7 - Credit Facility (Details) [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	$7,000,000	'
Prepayment Penalty Rate	1.00%	'
Line Of Credit Facility Current Ratio Covenant	1.75	'
Line of Credit Facility, Amount Outstanding	6,234,000	6,000,000
Receivable Financing Facility [Member]	'	'
Note 7 - Credit Facility (Details) [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	3,000,000	'
Line Of Credit Facility, Minimum Borrowing Base Requirement, Percentage Of Eligible Accounts Receivable	80.00%	'
Debt Instrument, Basis Spread on Variable Rate	0.25%	'
Debt Instrument, Basis Spread on Variable Rate (in Basis Points)	0.25%	'
Working Capital Facility [Member]	'	'
Note 7 - Credit Facility (Details) [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	4,000,000	'
Debt Instrument, Basis Spread on Variable Rate	2.00%	'
Debt Instrument, Basis Spread on Variable Rate (in Basis Points)	2.00%	'
Line Of Credit Facility Minimum Monthly Interest Charge	$2,000	'
Minimum [Member] | Receivable Financing Facility [Member]	'	'
Note 7 - Credit Facility (Details) [Line Items]	'	'
Line of Credit Facility, Interest Rate During Period	3.25%	'

Note_8_Restructuring_Details

Note 8 - Restructuring (Details) (USD $)	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Mar. 31, 2013
		Paid [Member]	Paid [Member]	Paid [Member]
Note 8 - Restructuring (Details) [Line Items]	'	'	'	'
Severance Costs	$0.30	$0.20	$0.20	$0.10

Note_8_Restructuring_Details_S

Note 8 - Restructuring (Details) - Summary of Changes in the Companybs Restructuring Liability (USD $)	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			Fiscal 2013 [Member]	Fiscal 20134 [Member]
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Balance as of March 31, 2013	$49	$232	$232	'
New charges	'	'	'	227
Cash paid	'	'	-232	-178
Balance as of December 31, 2013	$49	$232	'	$49

Note_9_Commitments_and_Conting1

Note 9 - Commitments and Contingencies (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2014
In Millions, unless otherwise specified			Subsequent Event [Member]
			Capital Lease Obligations [Member]
Note 9 - Commitments and Contingencies (Details) [Line Items]	'	'	'
Commitments and Contingencies	'	'	$0.30

Note_10_Redeemable_Convertible1

Note 10 - Redeemable Convertible Preferred Stock and Warrants (Details) (USD $)

0 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Sep. 12, 2013

Dec. 31, 2013

Sep. 04, 2013

Sep. 12, 2013

31-May-13

Sep. 12, 2013

Sep. 12, 2013

Sep. 12, 2013

31-May-13

Sep. 10, 2013

31-May-13

31-May-13

31-May-13

Sep. 12, 2013

Sep. 12, 2013

Sep. 10, 2013

Series A Warrant (Member)

Series A Warrant (Member)

Series A Warrant (Member)

Series A Warrant (Member)

Series B Warrant (Member)

Series B Warrant (Member)

Series B Warrant (Member)

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Series C Convertible Preferred Stock [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Second Closing (Member)

Series C Convertible Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

First Closing (Member)

Purchase Agreement (Member)

Second Closing (Member)

Second Closing (Member)

Second Closing (Member)

Second Closing (Member)

First Closing (Member)

Purchase Agreement (Member)

Purchase Agreement (Member)

Note 10 - Redeemable Convertible Preferred Stock and Warrants (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Number of Shares Issued in Transaction

'

'

'

'

'

'

'

'

231,518

'

'

577,105

'

'

'

'

Sale of Stock, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

$7

'

$7

$7

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

'

231,528

231,518

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

404,309

'

404,309

'

'

45,571

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

577,105

91,144

91,144

231,518

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)

'

'

7.75

7.75

'

7.75

7.75

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

7.75

7.75

'

7.75

7.75

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms

'5 years

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_11_StockBased_Compensatio2

Note 11 - Stock-Based Compensation (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Sep. 04, 2013

Jun. 30, 2013

31-May-13

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Aug. 31, 2013

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

ESPP [Member]

ESPP [Member]

CEO and COO [Member]

Note 11 - Stock-Based Compensation (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

216,000

0

266,000

0

'

'

'

'

'

'

'

'

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term

'

'

'6 years 73 days

'

'

'

'

'

'

'

'

'

Share Price (in Dollars per share)

$6.41

'

$6.41

'

$5.49

$9

$8.60

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

$100,000

$200,000

$100,000

$200,000

'

'

'

$3,700,000

$4,700,000

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

'

'

'

'

'

'

'

-500,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

2,700,000

'

2,700,000

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'3 years 36 days

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date

'

'

'

'

'

'

'

'

'

'

85.00%

'

Share-based Compensation

'

'

$902,000

$699,000

'

'

'

'

'

$19,000

$115,000

'

Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)

'

'

28,901

0

'

'

'

'

'

'

'

'

Note_11_StockBased_Compensatio3

Note 11 - Stock-Based Compensation (Details) - Stock Option and Restricted Units	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Stock Option and Restricted Units [Abstract]	'	'	'	'
Stock Options	216,000	0	266,000	0
Restricted Stock Units	261,000	449,000	472,000	623,000
Total Granted	477,000	449,000	738,000	623,000

Note_11_StockBased_Compensatio4

Note 11 - Stock-Based Compensation (Details) - Stock Options Valuation Assumptions (USD $)	3 Months Ended				9 Months Ended
	Dec. 31, 2013	Sep. 04, 2013	Jun. 30, 2013	31-May-13	Dec. 31, 2013
Stock Options Valuation Assumptions [Abstract]	'	'	'	'	'
Risk-free interest rate	0.91%	1.74%	1.41%	1.05%	0.88%
Dividend yield	0.00%	'	'	'	0.00%
Expected volatility	58.21%	76.70%	76.00%	76.00%	58.43%
Expected term in years	'3 years 76 days	'	'	'	'3 years 76 days
Weighted average fair value at grant date (in Dollars per share)	$2.56	'	'	'	$2.52

Note_11_StockBased_Compensatio5

Note 11 - Stock-Based Compensation (Details) - Activity Under The Equity Incentive Plans (USD $)	3 Months Ended		9 Months Ended		3 Months Ended			0 Months Ended	1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013		Dec. 04, 2013	Dec. 31, 2013
					Restricted Stock Units (RSUs) [Member]	Employee Stock Option [Member]		NonQualified Employee Stock Option [Member]	NonQualified Employee Stock Option [Member]
								Chief Executive Officer [Member]	Chief Executive Officer [Member]
Note 11 - Stock-Based Compensation (Details) - Activity Under The Equity Incentive Plans [Line Items]	'	'	'	'	'	'		'	'
Outstanding at September 30, 2013	844,000	'	'	'	'	'		'	'
Outstanding at September 30, 2013	618,000	'	'	'	'	'		'	'
Outstanding at September 30, 2013 (in Dollars per share)	$6.97	'	'	'	'	'		'	'
Restricted stock units granted	-261,000	-449,000	-472,000	-623,000	-261,000	'		'	'
Restricted stock units granted	261,000	449,000	472,000	623,000	261,000	'		'	'
Restricted stock units released	'	'	'	'	-48,000	'		'	'
Restricted stock units cancelled	'	'	'	'	83,000	'		'	'
Restricted stock units cancelled	'	'	'	'	-83,000	'		'	'
Options granted- Shares Available for share	-216,000	0	-266,000	0	'	-216,000	[1]	-186,979	187,000	[1]
Options granted-Number of Shares	216,000	0	266,000	0	'	216,000	[1]	186,979	-187,000	[1]
Options granted-Weighted average exercise price (in Dollars per share)	'	'	'	'	'	$6.28	[1]	'	'
Options exercised	'	'	'	'	'	-18,000		'	'
Options exercised (in Dollars per share)	'	'	'	'	'	$5.42		'	'
Options cancelled	'	'	'	'	'	21,000		'	'
Options cancelled	'	'	'	'	'	-21,000		'	'
Options cancelled (in Dollars per share)	'	'	'	'	'	$10.28		'	'
Outstanding at December 31, 2013	658,000	'	658,000	'	'	'		'	'
Outstanding at December 31, 2013	925,000	'	925,000	'	'	'		'	'
Outstanding at December 31, 2013 (in Dollars per share)	$6.41	'	$6.41	'	'	'		'	'
[1]	includes 186,979 shares granted to Mr. Blaine Mathieu as part of his employment agreement. For more information refer to Footnote 16.

Note_11_StockBased_Compensatio6

Note 11 - Stock-Based Compensation (Details) - Options Outstanding and Exercisable, by Exercise Range (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding and Exercisable Range of Exercise Price Minimum	$3.70
Options Outstanding and Exercisable Range of Exercise Price Maximum	$34
Options Outstanding, Number of Shares (in Shares)	342
Options Outstanding, Weighted-Average Remaining Contractual Life	'9 years 10 days
Options Vested and Exercisable, Number of Shares (in Shares)	68
Options Vested and Exercisable, Weighted-Average Exercise Price	$7.57
Range One [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding and Exercisable Range of Exercise Price Minimum	$3.70
Options Outstanding and Exercisable Range of Exercise Price Maximum	$5.72
Options Outstanding, Number of Shares (in Shares)	109
Options Outstanding, Weighted-Average Remaining Contractual Life	'8 years 58 days
Options Vested and Exercisable, Number of Shares (in Shares)	51
Options Vested and Exercisable, Weighted-Average Exercise Price	$5.18
Range Two [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding and Exercisable Range of Exercise Price Minimum	$5.93
Options Outstanding and Exercisable Range of Exercise Price Maximum	$5.93
Options Outstanding, Weighted-Average Remaining Contractual Life	'65 days
Options Vested and Exercisable, Weighted-Average Exercise Price	$5.93
Range Three [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding and Exercisable Range of Exercise Price Minimum	$6.28
Options Outstanding and Exercisable Range of Exercise Price Maximum	$6.28
Options Outstanding, Number of Shares (in Shares)	187
Options Outstanding, Weighted-Average Remaining Contractual Life	'9 years 335 days
Range Four [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding and Exercisable Range of Exercise Price Minimum	$6.30
Options Outstanding and Exercisable Range of Exercise Price Maximum	$31.30
Options Outstanding, Number of Shares (in Shares)	44
Options Outstanding, Weighted-Average Remaining Contractual Life	'7 years 281 days
Options Vested and Exercisable, Number of Shares (in Shares)	15
Options Vested and Exercisable, Weighted-Average Exercise Price	$13.05
Range Five [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding and Exercisable Range of Exercise Price Minimum	$34
Options Outstanding and Exercisable Range of Exercise Price Maximum	$34
Options Outstanding, Number of Shares (in Shares)	2
Options Outstanding, Weighted-Average Remaining Contractual Life	'1 year 18 days
Options Vested and Exercisable, Number of Shares (in Shares)	2
Options Vested and Exercisable, Weighted-Average Exercise Price	$34

Note_11_StockBased_Compensatio7

Note 11 - Stock-Based Compensation (Details) - Effect of Recording Stock-Based Compensation Expense (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Operating expenses	$3,986	$3,577	$12,256	$10,683
Cost of Revenues (Member)	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Operating expenses	76	32	191	89
Research and Development (Member)	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Operating expenses	43	39	131	113
Sales and Marketing (Member)	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Operating expenses	108	93	238	199
General and Administrative (Member)	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Operating expenses	239	174	361	298
Impact on Net Loss (Member)	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Operating expenses	$466	$338	$921	$699

Note_11_StockBased_Compensatio8

Note 11 - Stock-Based Compensation (Details) - ESPP Valuation Assumptions (USD $)	3 Months Ended				9 Months Ended
	Dec. 31, 2013	Sep. 04, 2013	Jun. 30, 2013	31-May-13	Dec. 31, 2013
Note 11 - Stock-Based Compensation (Details) - ESPP Valuation Assumptions [Line Items]	'	'	'	'	'
Risk-free interest rate	0.91%	1.74%	1.41%	1.05%	0.88%
Dividend yield	0.00%	'	'	'	0.00%
Expected volatility	58.21%	76.70%	76.00%	76.00%	58.43%
Expected term in years	'3 years 76 days	'	'	'	'3 years 76 days
Weighted average fair value at grant date (in Dollars per share)	$2.56	'	'	'	$2.52
ESPP [Member]	'	'	'	'	'
Note 11 - Stock-Based Compensation (Details) - ESPP Valuation Assumptions [Line Items]	'	'	'	'	'
Risk-free interest rate	0.04%	'	'	'	0.08%
Dividend yield	0.00%	'	'	'	0.00%
Expected volatility	61.90%	'	'	'	59.40%
Expected term in years	'6 months	'	'	'	'6 months
Weighted average fair value at grant date (in Dollars per share)	$2.74	'	'	'	$2.86

Note_12_Comprehensive_Settleme1

Note 12 - Comprehensive Settlement Agreement (Details) (Versata Settlement Agreement [Member], USD $)	6 Months Ended	12 Months Ended
	Dec. 31, 2012	Mar. 31, 2012
Versata Settlement Agreement [Member]	'	'
Note 12 - Comprehensive Settlement Agreement (Details) [Line Items]	'	'
Repayments of Other Debt	'	$4,500,000
Payments for Repurchase of Common Stock	'	472,000
Professional and Contract Services Expense	$500,000	$500,000

Note_13_Income_Taxes_Details

Note 13 - Income Taxes (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]	'
Unrecognized Tax Benefits	$2.10

Note_14_Computation_of_Basic_a2

Note 14 - Computation of Basic and Diluted Net Loss per Share (Details) - Antidilutive Securities Excluded from The Computation of Earnings Per Share	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities	598	488	384	275
Equity Option [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities	145	45	71	'
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities	21	443	23	275
Warrant [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities	432	'	290	'

Note_16_Other_Events_Details

Note 16 - Other Events (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 04, 2013	Dec. 31, 2013		Dec. 04, 2013	Dec. 04, 2013
					NonQualified Employee Stock Option [Member]	NonQualified Employee Stock Option [Member]		Chief Executive Officer [Member]	Chief Executive Officer [Member]
					Chief Executive Officer [Member]	Chief Executive Officer [Member]		Annual Salary [Member]	Incentive Bonus [Member]
Note 16 - Other Events (Details) [Line Items]	'	'	'	'	'	'		'	'
Salaries, Wages and Officers' Compensation	'	'	'	'	'	'		$300,000	$150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	216,000	0	266,000	0	186,979	-187,000	[1]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	'	'	'	'	'10	'		'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'	'48 months	'		'	'
[1]	includes 186,979 shares granted to Mr. Blaine Mathieu as part of his employment agreement. For more information refer to Footnote 16.

Note_17_Subsequent_Events_Deta

Note 17 - Subsequent Events (Details) (USD $)

Dec. 31, 2013

Sep. 04, 2013

Jun. 30, 2013

31-May-13

Mar. 31, 2013

Apr. 15, 2014

Jan. 24, 2014

Apr. 15, 2014

Jan. 24, 2014

Jan. 23, 2014

Jan. 24, 2014

Jan. 24, 2014

Jan. 24, 2014

Apr. 15, 2014

Jan. 24, 2014

Jan. 24, 2014

Apr. 15, 2014

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Conversion Rate Numerator [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Convertible Preferred Stock Series D [Member]

Convertible Preferred Stock Series D [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

The 2014 Financing [Member]

Issued Warrants to Purchase Common Stock [Member]

Series D Preferred Stock [Member]

The 2014 Financing [Member]

The 2014 Financing [Member]

Placement Agent Compensation for 2014 Financing [Member]

The 2014 Financing [Member]

Purchase Agreement [Member]

Placement Agent Compensation for 2014 Financing [Member]

Placement Agent Compensation for 2014 Financing [Member]

The 2014 Financing [Member]

Note 17 - Subsequent Events (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

765,605

'

'

'

'

68,047

'

'

'

'

'

Sale of Stock, Price Per Share (in Dollars per share)

'

'

'

'

'

'

$6

'

'

'

$60

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8,700,000

'

'

Stockholders' Equity Attributable to Parent, Qualified for Net Capital (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,500,000

'

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

'

10

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$0.00

'

'

'

$0.00

'

'

'

'

$6

'

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

Share Price (in Dollars per share)

$6.41

$5.49

$9

$8.60

'

$60

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

723,030

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

'

'

'

7

'

'

'

'

'

'

'

'

'

Term of Warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

'

'

11,029

'

'

'

980.4

'

'

'

'

Debt Conversion, Converted Instrument, Warrants or Options Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,416

'